title: Dysadherin: expression and clinical significance in thyroid carcinoma.
abstract: Dysadherin is a cancer-associated cell membrane glycoprotein. Its cDNA encodes 178 amino acids, including a putative signal sequence, a potential O-glycosylated extracellular domain, a single transmembrane domain, and a short cytoplasmic tail. Dysadherin is believed to down-regulate the expression of E-cadherin, the prime mediator of cell-cell adhesion in epithelial cells, by a posttranscriptional mechanism and promote the metastasis of carcinoma cells. To evaluate the association between dysadherin expression and E-cadherin expression in thyroid carcinoma, immunostaining for dysadherin and E-cadherin was performed in 51 papillary, 10 follicular, and 31 undifferentiated carcinomas. Immunoreactivity for dysadherin, localized at cell-cell boundaries, was detected in 39 of the 51 papillary carcinomas and all 31 undifferentiated carcinomas but not in the follicular carcinomas or normal thyroid tissue controls. Dysadherin expression was significantly higher in undifferentiated carcinoma than in papillary carcinoma and follicular carcinoma and showed significant negative correlation with E-cadherin expression. The degree of dysadherin expression was significantly associated with the prognosis, occurrence of secondary undifferentiated carcinomas, size of the primary tumor, and metastasis to the regional lymph nodes and lungs. In conclusion, a process involving increased dysadherin expression may lead to an adverse clinical outcome.
authors.affiliation: Pathology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Sato
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Ino
authors.forename: Ayaka
authors.initials: A
authors.lastname: Miura
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Abe
authors.forename: Hideto
authors.initials: H
authors.lastname: Sakai
authors.forename: Koichi
authors.initials: K
authors.lastname: Ito
authors.forename: Setsuo
authors.initials: S
authors.lastname: Hirohashi
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal; D015820:Cadherins / Q000096:biosynthesis; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000473:pathology; D018265:Carcinoma, Papillary, Follicular / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D007473:Ion Channels; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000502:physiology*; D008840:Microfilament Proteins; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000502:physiology*; D011379:Prognosis; D012727:Sex Characteristics; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D015820:Cadherins; C451410:FXYD5 protein, human; D007473:Ion Channels; D008562:Membrane Glycoproteins; D008840:Microfilament Proteins; D009363:Neoplasm Proteins